Abstract
Objective: In the past decade, several new anti-epileptic drugs (AEDs) were introduced in the Netherlands. These new drugs, one of which is lamotrigine, are 6 to 10 times more expensive than conventional anti-convulsants. In 1997, the high cost of lamotrigine, together with a lack of clinical data supporting its superiority over conventional drugs, prompted the Dutch Health Insurance Board to release a guideline in which the use of lamotrigine was restricted to difficult-to-treat patients. Other new drugs that were marketed after 1997 also became subject to this guideline. The utilisation of new AEDs and the cost consequences are the subject of this paper.
Methods: Data from extramurally prescribed AEDs was obtained from the Dutch Drug Information Project, which is a database containing prescriptions for about 5.5 million inhabitants of the Netherlands. This data was used to study the impact of new AEDs on volume and market share of AEDs in the period from 1995 to 2001 in the Netherlands.
Results: Between 1995 and 2001, the total volume of AEDs increased by 130%, 60% of which consisted of new AEDs. Gabapentin, lamotrigine and oxcarbazepine were the most frequently prescribed new compounds. The volume share of new AEDs increased from 5% in 1995 to 18% in 2001. The market share amounted to 21.5 million euros in 1995 and rose to 47 million euros in 2001; 80% of this increase was due to the introduction of new AEDs.
Discussion: Although in 2001 the volume share of new AEDs was still modest, their introduction has led to a strong increase in the cost. New data is emerging on the effectiveness and cost-benefit sum of the new AEDs; this may change the place in therapy of these drugs. Because of their strong potential to force up cost, the positioning of new AEDs requires further attention.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
RH Mattson JA Cramer JF. Collins (1992) ArticleTitleA comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group N Engl J Med 327 765–71 Occurrence Handle1:STN:280:By2A28rnsVI%3D Occurrence Handle1298221
RH Mattson JA Cramer JF. Collins et al. (1985) ArticleTitleComparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures N Engl J Med: 313 145–51 Occurrence Handle1:STN:280:BiqB2c%2Fkt1U%3D
D. Heaney (1999) ArticleTitleThe pharmacoeconomics of the new antiepileptic drugs Epilepsia. 40 IssueIDSuppl 8 25–31 Occurrence Handle10563592
IA Kotsopoulos SM Evers AJ. Ament et al. (2001) ArticleTitleEstimating the costs of epilepsy: an international comparison of epilepsy cost studies Epilepsia. 42 634–40 Occurrence Handle10.1046/j.1528-1157.2001.18200.x Occurrence Handle1:STN:280:DC%2BD3M3ps1aiuw%3D%3D Occurrence Handle11380571
DG Trenite TW Rentmeester FB. Scholtes et al. (2001) ArticleTitlePeri-marketing surveillance of lamotrigine in the Netherlands: doctors’ and patients’ viewpoints Pharm World Sci: 23 1–5 Occurrence Handle10.1023/A:1011258526637 Occurrence Handle1:STN:280:DC%2BD3M3ktV2ksw%3D%3D
World Health Organization, Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: WHO, 1998. Ref Type: Report
AK Mantel-Teeuwisse OH Klungel WM. Verschuren et al. (2001) ArticleTitleComparison of different methods to estimate prevalence of drug use by using pharmacy records J Clin Epidemiol. 54 1181–6 Occurrence Handle10.1016/S0895-4356(01)00396-1 Occurrence Handle1:STN:280:DC%2BD3MrmvVShsA%3D%3D Occurrence Handle11675171
E Beghi ML Monticelli G. Monza et al. (1991) ArticleTitleAntiepileptic drugs as ’tracers’ of disease. A calculation of the prevalence of epilepsy through an analysis of drug consumption. The Group for the Study of Epilepsy in General Practice. Neuroepidemiology 10 33–41 Occurrence Handle1:STN:280:By6B1cjos1c%3D Occurrence Handle2062415
R Banfi G Borselli C. Marinai et al. (1995) ArticleTitleEpidemiological study of epilepsy by monitoring prescriptions of antiepileptic drugs Pharm World Sci. 17 138–40 Occurrence Handle1:STN:280:BymD3czht10%3D Occurrence Handle7581220
MW Lammers YA Hekster A. Keyser et al. (1996) ArticleTitleUse of anti-epileptic drugs in a community-dwelling Dutch population Neurology. 46 62–7 Occurrence Handle1:STN:280:BymC2czhs1U%3D Occurrence Handle8559422
DP Shackleton RG Westendorp DG. Kasteleijn-Nolst Trenite et al. (1997) ArticleTitleDispensing epilepsy medication: a method of determining the frequency of symptomatic individuals with seizures J Clin Epidemiol. 50 1061–8 Occurrence Handle10.1016/S0895-4356(97)00116-9 Occurrence Handle1:STN:280:DyaK1c%2FivFehug%3D%3D Occurrence Handle9363041
SJ Roberts M Feely DN. Bateman (1998) ArticleTitlePrescribing of anti-epileptic drugs in the northern and Yorkshire region: 1992-1995 Seizure 7 127–32 Occurrence Handle10.1016/S1059-1311(98)80053-8 Occurrence Handle1:STN:280:DyaK1c3ovVyqsA%3D%3D Occurrence Handle9627203
P Rochat J Hallas D. Gaist et al. (2001) ArticleTitleAntiepileptic drug utilization: a Danish prescription database analysis Acta Neurol Scand. 104 6–11 Occurrence Handle10.1034/j.1600-0404.2001.00197.x Occurrence Handle1:STN:280:DC%2BD3MzovVGltw%3D%3D Occurrence Handle11442436
R Banfi G Borselli C. Marinai et al. (1995) ArticleTitleEpidemiological study of epilepsy by monitoring prescriptions of antiepileptic drugs Pharm World Sci. 17 138–40 Occurrence Handle1:STN:280:BymD3czht10%3D Occurrence Handle7581220
SR Botts J. Raskind (1999) ArticleTitleGabapentin and lamotrigine in bipolar disorder Am J Health Syst Pharm. 56 1939–44 Occurrence Handle1:CAS:528:DyaK1MXmslyqtb8%3D Occurrence Handle10554911
KC Gorson C Schott R. Herman et al. (1999) ArticleTitleGabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial J Neurol Neurosurg Psychiatry. 66 251–2 Occurrence Handle1:STN:280:DyaK1M7mvVKktg%3D%3D Occurrence Handle10071116
AC Pande JG Crockatt CA. Janney et al. (2000) ArticleTitleGabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy Gabapentin Bipolar Disorder Study Group Bipolar Disord. 2 249–55 Occurrence Handle10.1034/j.1399-5618.2000.20305.x Occurrence Handle1:STN:280:DC%2BD3M3ks1KjtQ%3D%3D Occurrence Handle11249802
DM Simpson R Olney JC. McArthur et al. (2000) ArticleTitleA placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy Neurology. 54 2115–9 Occurrence Handle1:CAS:528:DC%2BD3cXksVGisr0%3D Occurrence Handle10851374
L Ichim M Berk S. Brook (2000) ArticleTitleLamotrigine compared with lithium in mania: a double-blind randomized controlled trial Ann Clin Psychiatry. 12 5–10 Occurrence Handle10.1023/A:1009066725103 Occurrence Handle1:STN:280:DC%2BD3c3ls1Ogsg%3D%3D Occurrence Handle10798820
WE Meijer ER Heerdink LP. Pepplinkhuizen et al. (2001) ArticleTitlePrescribing patterns in patients using new antidepressants Br J Clin Pharmacol. 51 181–3 Occurrence Handle10.1111/j.1365-2125.2001.01329.x Occurrence Handle1:STN:280:DC%2BD3M3jsFKgtg%3D%3D Occurrence Handle11259993
H Petri J. Urquhart (1991) ArticleTitleChannelling bias in the interpretation of drug effects Stat Med. 10 577–81 Occurrence Handle1:STN:280:By6B1c%2FhslY%3D Occurrence Handle2057656
T Eke JF Talbot MC. Lawden (1997) ArticleTitleSevere persistent visual field constriction associated with vigabatrin BMJ. 314 180–1 Occurrence Handle1:STN:280:ByiC2svnslY%3D Occurrence Handle9022432
JM. Pellock (1999) ArticleTitleFelbamate in epilepsy therapy: evaluating the risks Drug Saf. 21 225–39 Occurrence Handle1:CAS:528:DyaK1MXmt1SjsL0%3D Occurrence Handle10487399
Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and car- 6
MJ Brodie JP. Mumford (1999) ArticleTitleDouble-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group Epilepsy Res. 34 199–205 Occurrence Handle10.1016/S0920-1211(98)00110-7 Occurrence Handle1:CAS:528:DyaK1MXhsVWktLk%3D Occurrence Handle10210035
M Reunanen M Dam AW. Yuen (1996) ArticleTitleA randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy Epilepsy Res. 23 149–55 Occurrence Handle10.1016/0920-1211(95)00085-2 Occurrence Handle1:CAS:528:DyaK28Xis1Wnu7g%3D Occurrence Handle8964276
TJ Steiner CI Dellaportas LJ. Findley et al. (1999) ArticleTitleLamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin Epilepsia. 40 601–7 Occurrence Handle1:CAS:528:DyaK1MXmt1Sjtbg%3D Occurrence Handle10386529
W Christe G Kramer U. Vigonius et al. (1997) ArticleTitleA double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy Epilepsy Res. 26 451–60 Occurrence Handle10.1016/S0920-1211(96)01013-3 Occurrence Handle1:CAS:528:DyaK2sXivFGls7k%3D Occurrence Handle9127726
M Dam R Ekberg Y. Loyning et al. (1989) ArticleTitleA double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy Epilepsy Res. 3 70–6 Occurrence Handle10.1016/0920-1211(89)90070-3 Occurrence Handle1:STN:280:BiaC3sjgt1w%3D Occurrence Handle2645120
R Gillham K Kane L. Bryant-Comstock et al. (2000) ArticleTitleA double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure Seizure. 9 375–9 Occurrence Handle10.1053/seiz.2000.0428 Occurrence Handle1:STN:280:DC%2BD3M%2FhvFOjug%3D%3D Occurrence Handle10985991
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Knoester, P., Deckers, C., Vaart, R.v.d. et al. Volume and market share of anti-epileptic drugs in the Netherlands: impact of new drugs. Pharm World Sci 27, 129–134 (2005). https://doi.org/10.1007/s11096-005-1558-7
Issue Date:
DOI: https://doi.org/10.1007/s11096-005-1558-7